The KAT6A/KAT6B inhibitor CTx-648 (PF-9363) blocked histone tail modifications, demonstrating anti-tumor activity in ER-positive BC, including cases resistant to endocrine therapy.69 This evidence concerns the gene KAT6A and breast cancer.